

**BIOGRAPHICAL SKETCH**

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.  
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Richard M. Hoffman, MD, MPH		POSITION TITLE Professor of Medicine	
eRA COMMONS USER NAME RMH9990			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Haverford College, Haverford, PA	BA	1980	British Literature
Johns Hopkins University School of Medicine, University of Washington, School of Public	MD MPH	1984 1992	Medicine Epidemiology

**A. Positions and Honors.****Positions and Employment**

1984-1985 Internship, Oregon Health Sciences University, Portland - Internal Medicine  
 1985-1987 Residency, Oregon Health Sciences University, Portland - Internal Medicine  
 1988-1989 Consulting/staff physician, Portland VA Medical Center, Portland - Internal Medicine  
 1989-1992 Fellowship, Seattle VA Medical Center, Seattle - Ambulatory Care  
 1989-1992 Acting Instructor, University of Washington School of Medicine, Seattle  
 1992-1994 Clinical Assistant Professor, Arizona Health Sciences University, Tucson - Internal Medicine  
 1992-1994 Director, General Medicine Fellowship, Arizona Health Sciences University, Tucson  
 1994-2000 Assistant Professor of Medicine, University of New Mexico, Albuquerque  
 1994-present Staff Physician, Albuquerque VA Medical Center, Albuquerque  
 2000-2006 Associate Professor of Medicine, University of New Mexico, Albuquerque  
 2005- Interim Director Cancer Prevention, University of New Mexico Cancer Center  
 2006- Professor of Medicine, University of New Mexico, Albuquerque

**Honors**

Phi Beta Kappa; Magna cum Laude; Fellow, American College of Physicians; Deputy Editor, Journal of General Internal Medicine; Associate Editor, ACP Journal Club

**B. Selected peer-reviewed publications (in chronological order).**

(Publications selected from 72 peer-reviewed publications)

1. Hoffman RM, Psaty BS, Kronmal RA. Modifiable risk factors for incident heart failure in the Coronary Artery Surgery Study. Arch Intern Med. 1994; 154:417-23.
2. Hoffman RM, Garewal HS. Antioxidants and the Prevention of Coronary Heart Disease. Arch Intern Med 1995; 155: 241-6.
3. Gilliland FD, Welsh DJ, Hoffman RM, Key CR. Rapid Rise and Subsequent Decline in Prostate Cancer Incidence Rates for New Mexico, 1989-1993. Cancer Epidemiol Biomarkers Prev 1995; 4:797-800.
4. Hoffman RM, Papenfuss MR, Buller DB, and Moon TE. Screening for Prostate Cancer. A Survey of Primary Care Physicians. Am J Prev Med Am J Prev Med 1996; 12: 277-81.
5. Hoffman RM, Blume P, Gilliland FD. Prostate-specific antigen testing practices and outcomes in a primary care clinic. J Gen Intern Med 1998; 13: 106-10.
6. Herman CJ, Hoffman RM, Altobelli K. Variation in recommendations for cancer screening among primary care physicians in New Mexico. J Comm Health 1999; 24: 253-67.

7. Hoffman RM, Garewal HS. Alpha-tocopherol supplementation for the secondary prevention of cardiovascular disease. *Prev Med* 1999; 29: 112-18
8. Gilliland FD, Hoffman RM, Hamilton A, Albertsen P, Eley JW, Stephenson RA, Harlan L, Stanford JL, Hunt WC, Potosky A. Predictors of extra-capsular extension of clinically localized prostate cancer following radical prostatectomy: results from the population-based Prostate Cancer Outcomes Study. *J Urol* 1999; 162:1341-5.
9. Hoffman RM, Gilliland FD. A population-based survey of prostate cancer screening in New Mexico. *J Comm Health* 1999 1999; 24: 409-19
10. Hoffman RM, Clanon DL, Peirce J, Frank J. Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with non-specific prostate-specific antigen levels. *J Gen Intern Med*. 2000; 15: 739-48
11. Hoffman RM, Gilliland FD, Eley JW, et al. Racial and Ethnic Differences in Advanced Stage Prostate Cancer. The Prostate Cancer Outcomes Study. *J Natl Cancer Inst*. 2001; 93:388-85
12. Hamilton AS, Stanford JL, Gilliland FD, Albertsen PC, Stephenson RA, Hoffman RM, et al. Health Outcomes after External Beam Radiation Therapy for Clinically Localized Prostate Cancer. Results from the Prostate Cancer Outcomes Study. *J Clin Oncol* 2001; 19: 2517-26.
13. Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, Gilliland FD, Eley JW, Stephenson RA, Hoffman RM. Health outcomes following primary androgen deprivation therapy: results from The Prostate Cancer Outcomes Study. *J Clin Oncol*. 2001; 19: 3750-7.
14. Clegg LX, Potosky AL, Harlan LC, Hankey BF, Hoffman RM, Stanford JL, Hamilton AS. Comparison of self-reported initial treatment with medical records: results from the Prostate Cancer Outcomes Study (PCOS). *Am J Epidemiol*. 2001; 154: 582-7.
15. Ritzau J, Hoffman RM, Tzamaloukas AH. Eradication of staphylococcus aureus carriage and prevention of peritoneal catheter-related staphylococcal infections. *Perit Dial Int*. 2001; 21: 471-9.
16. Harlan LC, Potosky A, Gilliland FD, Hoffman R, et al. Factors associated with initial therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. *J Natl Cancer Inst* 2001; 93: 1864-71.
17. Inadomi J, Lavezo L, Swanson K, Hoffman RM, et al. Step-down management of gastroesophageal reflux disease. *Gastroenterol* 2001; 121:1095-1100
18. Potosky A, Reeve B, Clegg LX, Hoffman RM, et al. Treatment and outcomes among men managed without surgery or radiotherapy for localized prostate cancer: results from The Prostate Cancer Outcomes Study. *J Natl Cancer Inst*. 2002; 94: 430-7.
19. Hoffman RM, Clanon DL, Chavez M, Peirce JC. Using multiple cutpoints for the free-to-total prostate-specific antigen ratio improves the accuracy of prostate cancer detection. *Prostate*. 2002; 52: 150-8.
20. Hoffman RM, Gilliland FD, Adams-Cameron M, Hunt WC, Key C. Prostate-specific antigen testing accuracy in a population-based cohort. *BMC Fam Pract* 2002; 3: 19.
21. Hoffman RM, Shah JH, Wendel CS, et al. Evaluating once- and twice-daily self-monitored blood glucose testing strategies for stable insulin-treated patients with type 2 diabetes mellitus. The Diabetes Outcomes in Veterans Study. *Diabetes Care* 2002; 25: 1744-8.
22. Hoffman RM, Macdonald R, Slaton JW, Wilt TJ. Laser prostatectomy versus transurethral resection for treating benign prostatic obstruction. *J Urol* 2003; 169: 210-5.
23. Hoffman RM. An argument against routine prostate cancer screening. *Arch Intern Med* 2003; 163: 663-6.
24. Hoffman RM, Hunt WC, Gilliland FD, et al. Satisfaction with treatment decisions for clinically localized prostate cancer. Results from the Prostate Cancer Outcomes Study. *Cancer* 2003; 97:1653-62
25. Penson DF, Feng Z, Kuniyuki A, McClerran D, Albertsen PC, Deapen D, Gilliland F, Hoffman R, et al. General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the Prostate Cancer Outcomes Study. *J Clin Oncol* 2003; 21:1147-54.
26. Hoffman RM, Stone SN, Hunt WC, et al. Effects of misattribution in assigning cause of death on prostate cancer mortality rates. *Ann Epidemiol* 2003; 13: 450-4.
27. Stone SN, Hoffman RM, Tollestrup, et al. Family history of prostate cancer: a case-control study of Hispanic and non-Hispanic white men in New Mexico. *Ethn Dis* 2003; 13:233-9.
28. Murata GH, Shah JH, Wendel CS, Hoffman RM, et al. Assessing risk factors for poor glycemic control in stable, insulin-treated patients with type 2 diabetes. The Diabetes Outcomes in Veterans Study. *J*

- Diabetes Complications 2003; 7:186-91.
29. Murata GH, Shah JH, Hoffman RM, et al. Intensified blood glucose monitoring improves glycemic control in stable, insulin-treated veterans with type 2 diabetes. *Diabetes Care* 2003; 26:1759-63.
  30. Murata GH, Shah JH, Adam KD, Wendel CS, Bokhari SU, Solvas P, Hoffman RM, Duckworth WC. Factors affecting diabetes knowledge in patients with type 2 diabetes. *Diabetologia* 2003; 46: 1170-8.
  31. Tzamaloukas AH, Murata GH, Hoffman RM, et al. Classification of the degree of obesity by body mass index or by deviation from ideal weight. *Parenter Enteral Nutr* 2003; 27: 340-8.
  32. Hoffman RM, Harlan LC, Klabunde C, et al. Racial differences in initial treatment for clinically localized prostate cancer. Results from the Prostate Cancer Outcomes Study. *J Gen Intern Med* 2003; 18:845-53.
  33. Murata GH, Hoffman RM, Wendel CS, et al. Blood glucose self-monitoring predicts long-term risk for hypoglycemia in type 2 diabetes. *Arch Intern Med* 2004; 164: 1445-50.
  34. Murata GH, Duckworth WC, Shah JH, Wendel CS, Hoffman RM. Factors affecting hypoglycemia awareness in insulin-treated type 2 diabetes. *Diabetes Res Clin Pract* 2004; 65:61-7.
  35. Murata GH, Duckworth WC, Shah JH, Wendel CS, Hoffman RM. Sources of glucose variability in insulin-treated type 2 diabetes. The Diabetes Outcomes in Veterans Study. *Clin Endo* 2004; 60:451-6..
  36. Murata GH, Duckworth WC, Hoffman RM, et al. Weekly variation in the contribution of blood glucose to hemoglobin A1c in type 2 diabetes. *Am J Med Sci* 2004; 327:319-23.
  37. Legler JM, Davis WW, Potosky AL, Hoffman RM. Latent variable modeling of recovery trajectories: sexual function following radical prostatectomy. *Statistics in Medicine* 2004; 2:3875-93.
  38. Hoffman RM, Cameron-Adams M, Murata GH. Misclassifying Indications for Prostate-Specific Antigen Testing may Bias Case-Control Studies of Prostate Cancer Screening. *J Clin Epidemiol* 2004; 57:1071-5
  39. Potosky AL, Davis WW, Hoffman RM, et al. Five year health outcomes following surgery versus radiotherapy for clinically localized prostate cancer. The Prostate Cancer Outcomes Study (PCOS). *J National Cancer Inst* 2004; 64: 6673-8
  40. Murata GH, Duckworth WC, Shah JH, Wendel CS, Mohler MJ, Hoffman RM. Hypoglycemia in stable, insulin-treated patients with type 2 diabetes. A prospective study of 1,662 episodes. *J Diabet Compl* 2005; 19:10-7
  41. Murata GH, Shah JH, Duckworth WC, Wendel CS, Mohler MJ, Hoffman RM. Adherence of type 2 diabetic veterans to the 2003 dietary recommendations of the American Diabetes Association. The Diabetes Outcomes in Veterans Study (DOVES). *J Am Dietetic Assoc* 2004; 104:1816-26.
  42. Hoffman RM, MacDonald R, Monga M, Wilt TJ. Transurethral microwave thermotherapy versus transurethral resection for treating benign prostatic hyperplasia. *BJU Int* 2004; 94:1031-6.
  43. Hoffman RM, Gilliland FD, Penson DF, et al. Cross-sectional and longitudinal comparisons of health-related quality of life between prostate cancer patients and matched controls. *Cancer* 2004; 101:2011-9.
  44. Kang T, Gilliland FD, Hoffman RM, et al. Racial/ethnic differences in health-related quality of life during the five years after diagnosis of clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. *J Clin Onc* 2004; 22:4193-4201
  45. Hoffman RM, Stone SN, Herman C, Jung AM, Cotner J, Espey D, Kozoll R, Gavin MW. New Mexico's capacity for increasing the prevalence of colorectal cancer screening with screening colonoscopy. *Prev Chronic Dis*. [serial online] 2005; 2(1):A07.
  46. Hoffman RM, Stone SN, Espey D, Potosky AL. Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA. *BMC Cancer* 2005; 5(1):27.
  47. Penson DF, McClerran D, Feng Z, Li L, Albertsen PC, Gilliland F, Hamilton A, Hoffman RM, Stephenson R, Potosky AL, Stanford JL. Five-year urinary and sexual outcomes after radical prostatectomy: Results from the Prostate Cancer Outcomes Study. *J Urol*. *J Urol* 2005; 173: 1701-5.
  48. Stephenson RA, Mori M, Hsieh Y-C, Beer TM, Stanford JL, Gilliland FD, Hoffman RM, Potosky AL. Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the SEER Prostate Cancer Outcomes Study (PCOS). *J Urol* 2005; 174:646-50.
  49. Hoffman RM. Viewpoint: limiting prostate cancer screening. *Ann Intern Med* 2006; 144:438-44.
  50. Hoffman RM, Barry MJ, Stanford JL, Hamilton AS, Hunt WC, McNaughton Collins M. Health outcomes in older men with localized prostate cancer. Results from the Prostate Cancer Outcomes Study. *Am J Med* 2006; 119:418-25
  51. Wendel CS, Shah JH, Duckworth WC, Hoffman RM (corresponding author), Mohler MJ, Murata GH.

- Racial and ethnic disparities in the control of cardiovascular risk factors in southwestern veterans with type 2 diabetes: the Diabetes Outcomes in Veterans Study. BMC Health Services Research 2006, 6:58
52. Denberg TD, Glode LM, Steiner JF, Crawford ED, Beaty BL, Hoffman RM. Trends and predictors of aggressive therapy for clinically locally advanced prostate carcinoma. BJU Int 2006; 98: 335-40.
53. Denberg TD, Melhado TV, Kim FJ, Flanigan RC, Fairclough D, Beaty BL, Steiner JF, Hoffman RM. The influence of patient race and social vulnerability on urologist treatment recommendations in localized prostate carcinoma. Med Care 2006; 44:1137-41.
54. Denberg TD, Flanigan RC, Kim FJ, Hoffman RM, Steiner JF. Self-reported volume of radical prostatectomy among urologists in the USA. BJU Int 2007;99:339-43.
55. Hoffman RM, Denberg T, Hunt WC, Hamilton AS. Prostate cancer testing following a negative prostate biopsy: overtesting the elderly. J Gen Intern Med 2007; 22:1139-43.
56. Yee EFT, White RE, Murata GH, Handanos C, Hoffman RM. Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy. J Gen Intern Med 2007; July 17 [epub ahead of print]

### C. Research Support.

#### Ongoing research support

1R01CA114524-01A2 Penson (PI) 8/1/07-7/31/10

NIH/NCI

Race, comorbidity & long term prostate cancer outcomes

This project will obtain long-term follow-up on health-related quality of life outcomes in a population-based cohort diagnosed in the mid 1990s.

Role: Site Principal Investigator

1R21CA121066-01A2 Rhyne (PI) 11/1/07-10/31/09

NCI

Colorectal Cancer Screening in Southwest Hispanics and American Indians

This project will identify facilitators and barriers to colorectal cancer screening in minority populations

Role: Co-investigator

Merit Review. Mohler (PI) 5/1/05-4/30/08

VA HSR&D

Insulin Treatment Variation in Southwestern Diabetics: Therapeutic Decision-making

Role: Co-investigator

#### Completed Research Support

RFA-HS-04-011 Arora (PI) 9/30/04-9/29/07

AHRQ

Transforming healthcare quality through information technology.

This project will evaluate the safety of treating hepatitis C through telemedicine

Role: Consultant

PAR-02-042 Hoffman (PI) 4/1/04-3/31/06

NIH/NCI

Primary care colorectal cancer screening surveillance system

This project will collect electronic data on colorectal cancer screening practices and outcomes from a federal institution, university hospital, and HMO.

Role: Principal Investigator